Skip to main content

Table 2 Association of clinical diagnosis and the immunohistochemical expression of PAX-8

From: Immunohistochemical expression of PAX-8 in Sudanese patients diagnosed with malignant female reproductive tract tumors

  PAX 8 results no. (%) Total no. 60 P value
Positive Negative
Cancer histological type
 SCC 3 (6.7) 42 (93.3) 45 (75.0)  < 0.001
 Adenocarcinoma 11 (73.3) 4 (26.7) 15 (25.0)
Cancer site
 Cervix 8 (15.7) 43 (84.3) 51 (85.0)  < 0.001
 Endometrium 5 (100) 0 (0.0) 5 (8.3)
 Ovary 1 (25.0) 3 (75.0) 4 (6.7)
FIGO staging
 Stage 1 1 (33.3) 2 (66.7) 3 (5.0) 0.034
 Stage 2A 0 (0.0) 6 (100) 6 (10.0)
 Stage 2B 3 (21.4) 11 (78.6) 14 (23.3)
 Stage 3A 2 (25.0) 6 (75.0) 8 (13.3)
 Stage 3B 2 (11.8) 15 (88.2) 17 (28.3)
 Stage 4A 0 (0.0) 3 (100) 3 (5.0)
 Stage 4B 6 (66.7) 3 (33.3) 9 (15.0)
Cancer histopathological grading
 Well differentiated SCC 0 (0.0) 12 (100) 12 (20.0)  < 0.001
 Poorly differentiated SCC 2 (10.0) 18 (90.0) 20 (33.3)
 Moderately differentiated SCC 1 (7.7) 12 (92.3) 13 (21.7)
 Endometrium adenocarcinoma 9 (81.8) 2 (18.2) 11 (18.3)
 Endocervical adenocarcinoma 1 (100) 0 (0.0) 1 (1.7)
 Metastatic adenocarcinoma 0 (0.0) 2 (100) 2 (3.3)
 Ovarian mucinous cyst adenocarcinoma 1 (100) 0 (0.0) 1 (1.7)
  1. SCC Squamous Cell Carcinoma